IMCR News and Press, Immunocore Holdings plc From 11/11/21

P RESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pi...

Immunocore (NASDAQ:IMCR): Q3 GAAP EPS of -$0.93 beats by $0.21. Revenue of $7.98M(-11% Y/Y) beats by $0.62M. Press Release For further details see: Immunocore EPS beats by $0.21, beats on revenue

PRESS RELEASE Immunocore Reports Third Quarter 202 1 Financial Results and Provides Business Update Biologics License Application (BLA) and Market ing Authorisation Application (MAA) submission s accepted ...

P RESS RELEASE RESS RELEASE Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma ( mCM ) and uveal melanoma ( mUM ) at t he Society for Immunotherapy of Cancer (SITC) 36th Annua...

PRESS RELEASE Immunocore and Medison Pharma Partner for F uture Commercializ ation of Tebentafusp in Canada , Central Eastern Europe , and Israel (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US ...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval. Current valuation is fair given their market cap and pipeline, but longer-term outlook remains bullish. F...

Press Release Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine Tebentafusp demonstrated prolonged overall survival (OS) compared to investigat...

PRESS RELEASE Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA ( ctDNA ) while on tebentafusp is associated with o veral...

PRESS RELEASE Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US 13 September 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-...